CGM for Adults with Type 2 Diabetes Not on Insulin Therapy: The CONNECT Randomized Controlled Trial

by Prateek Chopra | June 24, 2026 | Diabetes Conferences | ADA 2026 Study Objective Trial Design Study Assessments Baseline Characteristics Baseline Medication Use Clinical Implications Baseline findings from the CONNECT trial highlight persistent gaps in glycemic management among adults with non-insulin-treated T2D. The ongoing study will determine whether CGM can improve glycemic outcomes and support more effective diabetes management […]

CGM for Adults with Type 2 Diabetes Not on Insulin Therapy: The CONNECT Randomized Controlled Trial Read Post »

Leave a Comment / Diabetes Conferences / / / , , , , ,

Prescribing Trends and Comparative Risk of Type 2 Diabetes Progression in Prediabetes by Antihyperglycemic Drug Class

by Prateek Chopra | June 24, 2026 | Diabetes Conferences | ADA 2026 Need for Diabetes Prevention Methods Primary Outcome Risk of Progression to Type 2 Diabetes Clinical Implications In this large real-world analysis, GLP-1RAs, GIP/GLP-1RAs, and SGLT2 inhibitors were associated with significantly lower rates of incident T2D compared with metformin. Among these therapies, GIP/GLP-1RAs provided the greatest protection against

Prescribing Trends and Comparative Risk of Type 2 Diabetes Progression in Prediabetes by Antihyperglycemic Drug Class Read Post »

Leave a Comment / Diabetes Conferences / / / , , , , ,

ABC Transporters as Surrogate Biomarkers of HDL Functionality for EarlyAtherosclerosis Risk Assessment in Type 2 Diabetes Mellitus

by Prateek Chopra | June 24, 2026 | Diabetes Conferences | ADA 2026 Clinical Significance Study Population Methods ABC Transporter Levels and HDL Functionality Impact on HDL Functionality Discriminatory Performance Clinical Implications Individuals with T2DM, particularly those with atherosclerosis, exhibited impaired HDL functionality despite similar HDL-C levels. Lower circulating ABCA1 and ABCG1 levels were associated with reduced cholesterol efflux capacity,

ABC Transporters as Surrogate Biomarkers of HDL Functionality for EarlyAtherosclerosis Risk Assessment in Type 2 Diabetes Mellitus Read Post »

Leave a Comment / Diabetes Conferences / / / , , , , ,

The Cardioprotective Effect of Glucagon-Like Peptide 1 Receptor Agonist ina Trial Inspired, And Wider, Population Individuals Living with Type 2Diabetes: A Target Trial Emulation Study in CPRD

by Prateek Chopra | June 23, 2026 | Diabetes Conferences | ADA 2026 Clinical Context Methods Study Population Cardiovascular Outcomes in the Trial-Matched Cohort Cardiovascular Outcomes in the Non-Trial Cohort Clinical Implications GLP-1RA therapy was associated with a lower risk of major adverse cardiovascular events among individuals meeting LEADER trial eligibility criteria but not among those outside the trial population.

The Cardioprotective Effect of Glucagon-Like Peptide 1 Receptor Agonist ina Trial Inspired, And Wider, Population Individuals Living with Type 2Diabetes: A Target Trial Emulation Study in CPRD Read Post »

Leave a Comment / Diabetes Conferences / / / , , , , , ,

A1C and BMI Changes by Sociodemographic Groups Among Patients UsingGLP-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors(SGLT-2i) in a Large Integrated Health System

by Prateek Chopra | June 23, 2026 | Diabetes Conferences | ADA 2026 | 0 comments Clinical Relevance Methods Study Population Glycemic and Weight Outcomes Differences Across Demographic Groups Clinical Implications In a real-world healthcare setting, GLP-1 RA therapy was associated with clinically meaningful reductions in HbA1c and BMI among patients with T2DM and obesity. Greater benefits observed in specific racial, ethnic,

A1C and BMI Changes by Sociodemographic Groups Among Patients UsingGLP-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors(SGLT-2i) in a Large Integrated Health System Read Post »

Leave a Comment / Diabetes Conferences / / / , , , , ,

The Hypoglycemia Prevention Program (HPP) for Primary Care: Pilot Clinical Trial

by Prateek Chopra | June 22, 2026 | Diabetes Conferences | ADA 2026 | 0 comments Clinical Need Program Overview Intervention Components Patient Participation Key Findings Clinical Implications The EHR-integrated HPP was well accepted by patients and improved hypoglycemia prevention practices in primary care. Further studies are warranted to determine its long-term impact on reducing hypoglycemic events.

The Hypoglycemia Prevention Program (HPP) for Primary Care: Pilot Clinical Trial Read Post »

Leave a Comment / Diabetes Conferences / / / , , , ,

Putting It All Together: Strategies for Implementation

by Prateek Chopra | June 22, 2026 | Diabetes Conferences | ADA 2026 | 0 comments Person-Centered Care Framework: Foundations of E ective Implementation: Lifestyle Interventions: Weight Management Strategies: Role of Technology: Health-System Transformation: Equity and Access Considerations: Remaining Knowledge Gaps: Successful implementation of contemporary T2D care requires a personalized, multidisciplinary approach that combines lifestyle modification, evidence-based therapies, digital health technologies, and

Putting It All Together: Strategies for Implementation Read Post »

Leave a Comment / Diabetes Conferences / / / , , , ,

Personalized Approach to Treatment Based on IndividualCharacteristics and Associated Long-Term Conditions

by Prateek Chopra | June 21, 2026 | Diabetes Conferences | ADA 2026 | 0 comments Evolving Treatment Approach: Management of Atherosclerotic Cardiovascular Disease (ASCVD): Management of Heart Failure and Chronic Kidney Disease: Obesity-Focused Treatment Strategies: Factors Influencing Treatment Selection: Principles of Personalized Care: Personalized diabetes care enables treatment decisions to be aligned with each individual’s cardiovascular, renal, metabolic, and obesity-related risk

Personalized Approach to Treatment Based on IndividualCharacteristics and Associated Long-Term Conditions Read Post »

Leave a Comment / Diabetes Conferences / / / , , , ,

Interventions and Approaches to Type 2Diabetes Treatment

by Prateek Chopra | June 11, 2026 | Diabetes Conferences | ADA 2026 | 0 comments Treatment Paradigm Shift: Role of SGLT2 Inhibitors: Role of GLP-1 Receptor Agonists: Established Glucose-Lowering Therapies: Metformin: Sulfonylureas: Insulin: Principles of Individualized Care: Contemporary T2DM management extends beyond glycemic control to address cardiovascular, renal, and metabolic health. Individualized treatment strategies

Interventions and Approaches to Type 2Diabetes Treatment Read Post »

Leave a Comment / Diabetes Conferences / / / , , , ,

Insulin Resistance: A Cause or Consequence of Metabolic Dysfunction? A Genetic Perspective with Evidence for the Existence of Both

by Prateek Chopra | June 11, 2026 | Diabetes Conferences | ADA 2026 | 0 comments Research Objective: Sources of Evidence: Evidence for Primary Insulin Resistance: Evidence for Secondary Insulin Resistance: Insights from Polygenic Analyses: Implications for Diabetes Risk Stratification: Human genetic evidence indicates that insulin resistance arises through multiple biological pathways rather than a

Insulin Resistance: A Cause or Consequence of Metabolic Dysfunction? A Genetic Perspective with Evidence for the Existence of Both Read Post »

Leave a Comment / Diabetes Conferences / / / , , , ,
Scroll to Top